RAKOVINA THERAPEUTICS INC (RKV.CA) Stock Price, Forecast & Analysis
Canada - TSX Venture Exchange - TSX-V:RKV - CA75103L3092 - Common Stock
RKV.CA Key Statistics, Chart & Performance
The current stock price of RKV.CA is 0.13 CAD. In the past month the price increased by 30%. In the past year, price decreased by -93.5%.
RKV.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RKV.CA. When comparing the yearly performance of all stocks, RKV.CA is a bad performer in the overall market: 99.7% of all stocks are doing better.
RKV.CA Financial Highlights
Over the last trailing twelve months RKV.CA reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS decreased by -34.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -158.75% | ||
| ROE | -443% | ||
| Debt/Equity | 0.61 |
RKV.CA Forecast & Estimates
RKV.CA Ownership
About RKV.CA
Company Profile
Rakovina Therapeutics, Inc. focuses on the development of new cancer treatments based on novel DNA-damage response technologies. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2020-02-07. The company is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. The company is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
Company Info
RAKOVINA THERAPEUTICS INC
105 - 1008 Beach Avenue
Vancouver BRITISH COLUMBIA V6B 0A5 CA
Employees: 0
Phone: 16046190225
RAKOVINA THERAPEUTICS INC / RKV.CA FAQ
Can you describe the business of RAKOVINA THERAPEUTICS INC?
Rakovina Therapeutics, Inc. focuses on the development of new cancer treatments based on novel DNA-damage response technologies. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2020-02-07. The company is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. The company is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
Can you provide the latest stock price for RAKOVINA THERAPEUTICS INC?
The current stock price of RKV.CA is 0.13 CAD. The price increased by 8.33% in the last trading session.
Does RAKOVINA THERAPEUTICS INC pay dividends?
RKV.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of RKV stock?
RKV.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is RAKOVINA THERAPEUTICS INC worth?
RAKOVINA THERAPEUTICS INC (RKV.CA) has a market capitalization of 2.75M CAD. This makes RKV.CA a Nano Cap stock.